These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32460142)

  • 41. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
    Soyka M
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of buprenorphine/naloxone in opioid-dependent humans.
    Stoller KB; Bigelow GE; Walsh SL; Strain EC
    Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M; Mundin G; Sumner M
    Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine.
    Quattlebaum THN; Kiyokawa M; Murata KA
    Fam Pract; 2022 Mar; 39(2):292-294. PubMed ID: 34173647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF; Black RA; Severtson SG; Dart RC; Green JL
    J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescribing the Buprenorphine Monoproduct for Adverse Effects of Buprenorphine-Naloxone.
    Grande LA
    J Addict Med; 2022 Jan-Feb 01; 16(1):4-6. PubMed ID: 33758111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Buprenorphine and naloxone for heroin dependence.
    Johnson RE; McCagh JC
    Curr Psychiatry Rep; 2000 Dec; 2(6):519-26. PubMed ID: 11123005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.
    Rudolph KE; Shulman M; Fishman M; Díaz I; Rotrosen J; Nunes EV
    Addiction; 2022 Mar; 117(3):637-645. PubMed ID: 34338389
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 55. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
    Shearer D; Young S; Fairbairn N; Brar R
    Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 57. Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence.
    Robbins JL; Englander H; Gregg J
    J Am Board Fam Med; 2021 Feb; 34(Suppl):S141-S146. PubMed ID: 33622829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Buprenorphine/naloxone - one formulation that doesn't fit all: a case report.
    Braun HM; Taylor JL; Axelrath S
    Harm Reduct J; 2024 Jul; 21(1):143. PubMed ID: 39080714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine.
    Oakley B; Wilson H; Hayes V; Lintzeris N
    Drug Alcohol Rev; 2021 May; 40(4):567-571. PubMed ID: 33480051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
    Strain EC; Harrison JA; Bigelow GE
    Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.